RxDoctor Payments Data

Sherry Crowder

Psychiatric/Mental Health · San Angelo, TXNPI 1609057108

Payments from drug & device makers

$1,098in general payments, 2019–2025

Across 46 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$287
  • Johnson & Johnson$189
  • Neurocrine Biosciences, Inc.$152
  • Otsuka America Pharmaceutical, Inc.$113
  • Teva Pharmaceuticals USA, Inc.$110
  • AbbVie$101
  • plus $146 from 4 others

What the payments were for

  • Food & beverage$91083%
  • Education$18817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,098 in reported general payments places this provider in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$8,034
Medicare patients
48
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$135,578
Invega SustennaPaliperidone Palmitate11$30,606
Aripiprazole73$9,767
Lurasidone Hcl40$4,442
Divalproex Sodium ErDivalproex Sodium50$3,104
Oxcarbazepine68$2,774
Trazodone Hcl162$2,021
Olanzapine72$1,706
Clozapine22$1,690
Vilazodone Hcl11$1,654
Quetiapine Fumarate104$1,412
Bupropion XlBupropion Hcl70$1,289
Benztropine Mesylate98$1,280
Buspirone Hcl92$1,278
Prazosin Hcl60$1,065

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$152$135,57817 claims
Johnson & JohnsonInvega Sustenna$189$30,60611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →